Bristol-Myers Squibb (BMY) Stock Price, Quote, News & History | Benzinga

Bristol-Myers Squibb Co (BMY) — Q2 FY26 Earnings Call Live coverage with Benzinga. Q2 FY26 Results EPS: $2.04 (est. $1.61) — inline Revenue: $12.97B (est. $11.70B) — inline Reported: 2026-07-30 Recent Quarters Q1 FY26 (2026-04-30): EPS $1.58 vs est $1.43 · Rev $11.49B vs est $10.92B Q4 FY25 (2026-02-05): EPS $1.26 vs est $1.19 · Rev $12.50B vs est $12.27B Q3 FY25 (2025-10-30): EPS $1.63 vs est $1.51 · Rev $12.22B vs est $11.81B Q2 FY25 (2025-07-31): EPS $1.46 vs est $1.15 · Rev $12.30B vs est $11.39B About Bristol-Myers Squibb Co Bristol Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group. https://www.bms.com · New Jersey, NJ, USA · 32,500 employees Follow Benzinga X: https://x.com/Benzinga Facebook: https://www.facebook.com/Benzinga/ Instagram: https://www.instagram.com/benzinga/ ⚠️ Disclaimer: Investing in financial markets carries risk, and there are no guaranteed returns. All information is for educational purposes only and should not be taken as financial advice. Always do your own research and speak with a qualified financial advisor before making investment decisions. Only invest what you can afford to lose. Past performance does not guarantee future outcomes. #earnings #BMY #stocks #benzinga